Latest Releases
Jan 08, 2026
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
Read More »Jan 06, 2026
Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th
Read More »Jun 20, 2025
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
Read More »Jan 06, 2025
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Read More »Dec 16, 2024
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
Read More »Dec 16, 2024
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
Read More »Dec 16, 2024
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
Read More »Oct 16, 2024
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
Read More »Sep 09, 2024